Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-and Active-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS Paliperidone (3, 9 and 15 mg/Day) and Olanzapine (10mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-and Active-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS Paliperidone (3, 9 and 15 mg/Day) and Olanzapine (10mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2013

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paliperidone (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 27 Jun 2013 Results for the Taiwanese patient population presented at the 11th World Congress of Biological Psychiatry.
    • 30 Mar 2010 Actual patient numbers amended from 318 to 319 as reported by ClinicalTrials.gov.
    • 09 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top